Everolimus
Clear Cell Renal Carcinoma
Peking University First HospitalSmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
23 Active assets in the Clear Cell Renal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib University of California, San Francisco | Phase 3 | B |
Nivolumab Exelixis | Phase 2 | B |
Pazopanib Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 | B |
Zanzalintinib Kelly Fitzgerald, MD | Phase 2 | B |
Modified Vaccinia Virus Ankara-5T4 Antigen Oxford BioMedica | Phase 3 | B |
View all 39 →
Same molecule, other indications
Everolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →